Administration of iron in renal anemia

Mileta Poskurica; Dejan S Petrović; Mina Poskurica

doi:10.2298/4385

Mileta Poskurica Department of Urology and Nephrology, Clinical Center Kragujevac, Kragujevac, Serbia; Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
Dejan S Petrović Department of Urology and Nephrology, Clinical Center Kragujevac, Kragujevac, Serbia; Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
Mina Poskurica Department of Urology and Nephrology, Clinical Center Kragujevac, Kragujevac, Serbia; Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

DOI: https://doi.org/10.2298/4385

Keywords: anemia, renal insufficiency, chronic, iron, hematinics, treatment outcome,

References

de Benoist B, McLean E, Egli I, Cogswell M. Worldwide prevalence of anaemia 1993–2005. WHO global database on anaemia. Geneva: WHO; 2008.

Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration. Blood 2006; 107(5): 1747−50.

Yamanishi H, Iyama S, Yamaguchi Y, Kanakura Y, Iwatani Y. Total iron-binding capacity calculated from serum transferrin concentration or serum iron concentration and unsaturated iron-binding capacity. Clin Chem 2003; 49(1): 175−8.

O'Mara NB. Anemia in Patients With Chronic Kidney Disease. Diabet Spect 2008; 21(1): 112−9.

Nemet D, Bogdanić V, Labar B, Jakšić B. Erythrocyte disease in: Hematopoietic system and malignant tumors. In: Vrhovac B, Francetić I, Jakšić B, Labar B, Vucelić B, editors. Internal medi-cine. Zagreb: Naklada Ljevak; 2008. p. 931−51. (Serbian)

Poskurica M. Congestive heart failure in patients with impaired renal function. 2nd Serbian Congress of Nephrology, Bel-grade; 2012 October 11−14; Belgrade: Collection of Abstracts; 2012. p. 13. (Serbian)

Remuzzi G, Schiepanti A, Minetti L. Hematology cosequences of renal failure. In: Brener MB, Rector FC, editors. The Kidney. 7th ed. Philadelphia: Saunders. 2004. p. 2165−88.

Poskurica M. Terminal chronic renal insufficiency and associ-ated cardiovascular complications [subspecialization]. Belgrade: Faculty of Medicine, University of Belgrade; 1998. (Serbian)

Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, et al. Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascularrisk in patients with chronic kidney disease. Am Heart J 2005; 149(3): 408−13.

Sharp P, Srai S. Molecular mechanisms involved in intestinal iron absorption. World J Gastroenterol 2007; 13(35): 4716−24.

Swinkels DW, Wetzels JF. Hepcidin: a new tool in the manage-ment of anaemia in patients with chronic kidney disease. Nephrol Dial Transplant 2008; 23(8): 2450−3.

Crichton RR, Danielson GB, Geisser P. Iron Therapy-with Special Emphasis on Intravenous Administration. 4th ed. Bremen: Uni-Med Verlag; 2008.

Petrović D, Milovanović D, Miloradović V, Nikolić A, Petrović M, Đurđević P, et al. Cardio-renal syndrome type 2: etiopathogene-sis, diagnosis and treatment. Med Čas 2012; 46(1): 30−4. (Ser-bian)

Petrović D, Jagić N, Miloradović V, Nikolić A, Stojimirović B. Car-diorenal syndrome - definition, classification and basic princi-ples of therapy. Ser J Exp Clin Res 2010; 11(2): 67−71.

Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, et al.Revised European best practice guidelines for the man-agement of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 Suppl 2: ii1−47.

Hörl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007; 18(2): 382−93.

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153(1): 23−33.

KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney dis-ease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50(3): 471−530.

Pasricha SR, Flecknoe-Brown SC, Allen KJ, Gibson PR, McMahon LP, Olynyk JK, et al. Diagnosis and management of iron defi-ciency anaemia: a clinical update. Med J Aust 2010; 193(9): 525−32.

de Francisco AL. Individualizing anaemia therapy. Nephrol Dial Transplant Plus 2010; 3(6): 519−26.

Locatelli F, Covic A, Eckardt K, Wiecek A, Vanholder R. Anaemia management in patients with chronic kidney disease: a posi-tion statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24(2): 348−54.

Zoccali C, Abramowicz D, Cannata-Andia JB, Cochat P, Covic A, Eckardt K, et al. European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP). Nephrol Dial Transplant 2008; 23(7): 2162−6.

Radonjić V, Đurović D, Đukić Lj. eds. National Drug Register - NDR 2012. Belgrade: Medicines and Medical Devices Agency of Serbia, National Centre for Information on Medicines and Medical Devices; 2012.

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 2006; 47: S11−S145.

KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2(4): 279−335.

Macdougall IC, Ashenden M. Current and upcoming erythropoi-esis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis 2009; 16(2): 117−30.

Petrović D, Poskurica M, Stojimirović B. Left ventricular hypertro-phy in hemodialysis patients: risk factors and treatment. Med Investg 2011; 45(3): 30−5. (Serbian)

Jaćović S, Petrović D, Nikolić A, Miloradović V, Poskurica M. Cardio-renal anemia syndrome: etiopathogenesis, clinical sig-nificance and treatment. PONS Med J 2013; 10(2): 64−9. (Ser-bian)

Schaefer L, Schaefer MR. A primer on iron therapy. Nephrol Dial Transplant 2007; 22 (9): 2429-31.

Poskurica M. Etiopathogenesis and incidence of cardiovascular disease in terminal renal failure. Leskovac: School of Dialysis Leskovac 98: Novelties in Nephrology, 1998; (1): 1−15. (Ser-bian)